These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 15208798

  • 1. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitors post-myocardial infarction.
    Young JB.
    Cardiol Clin; 1995 Aug; 13(3):379-90. PubMed ID: 7585774
    [Abstract] [Full Text] [Related]

  • 4. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M, Petrescu L, Riviş AI, Suşan RM, Burghină D, Dan R, Cozma D, Drăgulescu SI.
    Rom J Intern Med; 2005 Aug; 43(3-4):187-98. PubMed ID: 16812979
    [Abstract] [Full Text] [Related]

  • 5. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 7. [Trials with ACE-inhibitors in acute myocardial infarction].
    Dalla Volta S.
    Cardiologia; 1994 Dec 15; 39(12 Suppl 1):149-55. PubMed ID: 7634258
    [Abstract] [Full Text] [Related]

  • 8. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
    Mazzotta G, Vecchio C.
    G Ital Cardiol; 1994 Jan 15; 24(1):59-70. PubMed ID: 8200499
    [Abstract] [Full Text] [Related]

  • 9. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 15; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 10. [Indications for ACE inhibitors in the postinfarct period].
    Ertl G, Gaudron P, Neubauer S, Hu K, Zdrojewski T, Horn M, Kochsiek K.
    Z Kardiol; 1994 Sep 15; 83 Suppl 4():65-74. PubMed ID: 7856283
    [Abstract] [Full Text] [Related]

  • 11. [Two year follow-up of acute ischemic syndrome without ST elevation].
    Tan HQ, Zhu J, Liang Y, Zhang Y, Liu LS, Chinese Coordinating Center of OASIS Registry.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):184-8. PubMed ID: 15854465
    [Abstract] [Full Text] [Related]

  • 12. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 13. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 29; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 14. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India.
    J Assoc Physicians India; 2006 Jun 29; 54():469-80. PubMed ID: 16909697
    [Abstract] [Full Text] [Related]

  • 15. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F, Loma-Osorio A, Vila J, López-Bescós L, Cuñat J, Rodríguez E, San José JM, Heras M, Marrugat J, Investigadores del PRIAMHO II.
    Rev Esp Cardiol; 2006 Apr 29; 59(4):313-20. PubMed ID: 16709383
    [Abstract] [Full Text] [Related]

  • 16. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
    Vermeer NS, Bajorek BV.
    J Clin Pharm Ther; 2008 Dec 29; 33(6):591-601. PubMed ID: 19138236
    [Abstract] [Full Text] [Related]

  • 17. Effect of ACE inhibition on neurohormones.
    Remme WJ.
    Eur Heart J; 1998 Sep 29; 19 Suppl J():J16-23. PubMed ID: 9796836
    [Abstract] [Full Text] [Related]

  • 18. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov 29; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 19. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Vachiéry JL.
    Rev Med Brux; 2003 Sep 29; 24(4):A249-52. PubMed ID: 14606288
    [Abstract] [Full Text] [Related]

  • 20. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 29; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.